Close Menu

Microsoft

The diagnostics firm is conducting a 1,000-person study to find T cell profiles associated with the immune response to COVID-19 and recovery from the disease.

The company is also participating in a study, being conducted at Hannover Medical School, investigating the genetics of susceptibility to COVID-19.

Prevencio said that the agreement with Microsoft involves sales of cardiac blood tests to hospitals, life science companies, and contract research organizations.

The company is also looking to expand the use of its FDA-approved ClonoSeq assay, which has US FDA approval for MRD detection in acute lymphocytic leukemia and multiple myeloma.

The commission includes Shire, Microsoft, and EURODIS Rare Diseases Europe, and will develop a roadmap "to help the rare disease field ... shorten the multiyear diagnostic journey."